Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha radiopharmaceuticals for cancer, today announced the abstract release for its oral presentation on June 1, at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The abstract describes interim results from Part 3 of the CONVERGE-01 Phase 2 trial of Ac-225 rosopatamab tetraxetan (CONV01-α) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received Lu-177-PSMA radioligand therapy (Lu-PSMA).
Convergent Therapeutics Names Andrew Davis Chief Business and Strategy Officer
Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the appointment of Andrew Davis as its Chief Business and Strategy Officer. Mr. Davis, who most recently served as Chief Business Officer at Dynavax Therapeutics, will be a member of Convergent's executive leadership team.
Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting
Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that results from its ongoing Phase 2 CONVERGE-01 trial of CONV01-α will be presented at the 2026 ASCO Annual Meeting. The oral presentation, scheduled for June 1 in Chicago, will highlight data from patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Lu-177 PSMA radioligand therapy.
Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors
Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, today announced the appointment of Michael Rossi to its Board of Directors. Mr. Rossi brings more than 30 years of experience in radiopharmaceuticals, drug development, and commercial leadership to Convergent, as the Company completes its Phase 2 study of CONV01-α, a prostate specific membrane antigen (PSMA)-targeted Actinium-225 (Ac-225) radioantibody in patients with metastatic castration-resistant prostate cancer (mCRPC).
